Redeye has updated its estimates for Carasent following the Q2 2024 report, which was quite undramatic. Carasent is starting to pick up steam, after a year of internal improvements, which now are starting to shine through in the reported numbers. We are aligned with the company’s own financial targets, as we deem them credible.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/